
News|Articles|December 1, 2004
New molecular entities: erlotinib, solifenacin, natalizumab
New molecular entities: erlotinib, solifenacin, natalizumab
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Music and painting dual art therapy improves cognitive and social functions of hospitalized schizophrenia patients, study suggests
2
Biosimilars in 2025: A year of firsts
3
Early ctDNA clearance signals stronger Ordspono responses in relapsed lymphomas
4
Low uptake of shingles vaccine despite strong value proposition for older adults
5






















































